Medical Devices China

China Carrier Screening Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

China Carrier Screening Market Industry Trends and Forecast to 2034: Segmented by (Test, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $223.0 Mn Placeholder estimate
Estimate 2025 $250.5 Mn 8.5% of the global market
Projected 2034 $711.5 Mn 184.1% Adds $461.0 Mn over 9 forecast years
CAGR 2025–2034 12.3% Faster than 66% of 173 Medical Devices markets here
Key players 5
  • China is 8.47% of the global market.
  • In APAC, the largest is China (this report) at $250.5 Mn.
  • Fastest growing: India at 14.4% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$461.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Carrier Screening Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $223.0 Mn — —
2025 (base) $250.5 Mn +$27.4 Mn —
2026 (forecast) $281.3 Mn +$30.8 Mn +12.3%
2027 (forecast) $315.9 Mn +$34.6 Mn +26.1%
2028 (forecast) $354.7 Mn +$38.9 Mn +41.6%
2029 (forecast) $398.3 Mn +$43.6 Mn +59%
2030 (forecast) $447.3 Mn +$49.0 Mn +78.6%
2031 (forecast) $502.4 Mn +$55.0 Mn +100.6%
2032 (forecast) $564.2 Mn +$61.8 Mn +125.2%
2033 (forecast) $633.5 Mn +$69.4 Mn +153%
2034 (forecast) $711.5 Mn +$77.9 Mn +184.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Carrier Screening Market Analysis at a glance
Market size, 2025$250.5 Mn placeholder estimate
Forecast, 2034$711.5 Mn placeholder estimate
Growth (CAGR), 2025–203412.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, condition and end user (see all)
Key playersMyriad Genetics, Inc., Natera, Invitae, Sema4 (GeneDx), Fulgent Genetics (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Carrier Screening Market Analysis Executive Summary

Carrier screening checks future parents for gene changes they could pass on, such as for cystic fibrosis or spinal muscular atrophy.

Key segments of the carrier Screening market include test (Expanded Panels and Targeted Screening) and condition (Cystic Fibrosis, SMA and Thalassemia).

Bar chart: China Carrier Screening market size, 2024–2034, placeholder estimates. $223.0 Mn in 2024, $250.5 Mn in 2025 and $711.5 Mn in 2034, 12.3% CAGR.
China Carrier Screening market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Carrier Screening Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the carrier Screening market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the carrier Screening market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the carrier Screening market.

Competitive Landscape for Carrier Screening Market in China

The carrier Screening market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Carrier Screening Market in China

Carrier Screening in China: rules and payment

Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2]

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how carrier Screening products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Carrier Screening right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Carrier Screening in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Carrier Screening market in China?
Placeholder estimate: about $250.5 Mn in 2025, rising to about $711.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Carrier Screening market in China growing?
Placeholder estimate: about 12.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Carrier Screening market report cover?
The report splits the market by test (Expanded Panels, Targeted Screening), condition (Cystic Fibrosis, SMA, Thalassemia, Fragile X) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Carrier Screening market?
Key players include Myriad Genetics, Inc., Natera, Invitae, Sema4 (GeneDx) and Fulgent Genetics.
What is driving the Carrier Screening market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the carrier Screening market.
Who regulates Carrier Screening in China?
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How much research is published on Carrier Screening?
PubMed lists 837 papers on Carrier Screening added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in China

See all

Related on genomics and maternal

See the topic